Abstract Claims Description Full Text

Abstract

The present invention provides formulations for the topical application of cyclosporin to skin tissue for treatment of autoimmune, T-cell mediated immune disease, and inflammatory conditions, and for producing prolonged skin allograft survival and wound healing. In addition, methods for the use of said formulations--in tandem with systemic applications of cyclosporin or without same--are suggested. The present invention also suggests alternative formulations and delivery systems for the efficacious treatment of the aforementioned conditions, and further suggests a model with which formulations may be tested.

Other References

• C. W. Hewitt et al., "Cyclosporine and Skin Allografts for the Treatment of Thermal Injury: I. Extensive Graft Survival with Low-Level Long-Term Administration and Prolongation in a Rat Burn Model", Transplantation 45: 13 (1988)
• A. D. Hess et al., "Mechanisms of Action of Cyclosporine: Effect on Cells of the Immune System and on Subcellular Events in T Cell Activation", Transpl. Proc. 20: 29 (1988)
• C. N. Ellis et al., "Cyclosporine Improves Psoriasis in a Double-Blind Study", JAMA 256: 3110 (1986)
• L. H. Toledo-Pereyra et al., "Prolongation of Kidney Transplant Survival by Cyclosporine A Graft Pretreatment", Transplantation 33: 330 (1982)
• R. D. Aldridge et al., "Inhibition of Contact Sensitivity Reactions to DNFB by Topical Cyclosporin Application in the Guinea-Pig", Clin. Exp. Immunol. 59: 23 (1985)
• C. S. Lai et al., "Long-Term Survival of Skin Allografts in Rats Treated with Topical Cyclosporine", 44: 83 (1987)
• X. F. Zhao et al., "The Prolongation of Skin Allograft Survival by Topical Use of Cyclosporine A", Transpl. Proc. 20: 670 (1988)
• E. Towpik et al., "Cyclosporine and Experimental Skin Allografts", Transpl. 40: 714 (1985)
• Biren et al., "Prolonged Viability of Human Skin Xenografts in Rats by Cyclosporine", J. Invest. Dermatol. 86: 611 (1986)
• M. Ried et al., "Cyclosporine Levels in Human Tissues of Patients Treated for One Week to One Year", Transpl. Proc. 15: 2434 (1983)
• J. Thivolet et al., "Effects of Cyclosporin on Bullous Pemphigoid and Pemphigus", Lancet 1: 334 (1985)
• J. I. Harper et al., "Cyclosporine for Psoriasis", Lancet 2: 981 (1984)
• A. W. Thompson et al., "Topical Cyclosporin and Immunologically Mediated Skin Disorders", Lancet 1: 1212 (1987)
• M. W. Mosteller et al., "Penetration of Topical Cyclosporine into the Rabbit Cornea, Aqueous Humor, and Serum", Arch Opthalmol 103: 101 (1985)
• S. Levinger et al., "Effects of Systemic Administration of Chlorambucil and Topical Application of Cyclosporin A on Corneal Graft Survival in Rabbits", Isr. J. Med. Sci. 21: 670 (1985)
• G. F. Babcock et al., "Prolongation of Skin and Graft Survival with Topical Immunosuppression", Seventh International Congress on Burn Injuries, Melbourne, Australia (Feb. 1986)
• S. Shuster, "Cyclosporine in Dermatology", Transpl. Proc. 20: 19 (1988)
• K. S. Black et al, "Transdermal Application of Cyclosporine Prolongs Skin Allograft Survival", Transpl. Proc. 20: 660 (1988)
• C. A. Biren et al., "Dermatologic Applications of Cyclosporine", Arch Dermatol. 122: 1028 (1986)
• R. D. Aldridge et al., "Cyclosporine and Skin Disease", Lancet 1: 160 (1985)
• W. Muller et al., "Cyclosporin A for Psoriasis", NEJM 301: 555 (1979